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Abstract 
WWTR1 (also called TAZ in publications. 
Therefore, TAZ is used in the following 
description) is a WW domaing-containing 
transcriptional coactivator, which was first 
identified as a 14-3-3 binding protein.  
TAZ is the downstream component in the Hippo 
pathway, and also has been found to interact with 
different pathways, such as Wnt, TGFbeta, etc. 
TAZ is involved in mesenchymal stem cell 
differentiation as well as tumorigenesis.  
High level of TAZ has been found in different 
cancers, such as breast cancer, colon cancer, lung 
cancer, etc. 
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Identity 
Other names: TAZ 
HGNC (Hugo): WWTR1 
Location: 3q25.1 
Local order 
TM4SF4-WWTR1-COMMD2-ANKUB1. 
DNA/RNA 
Description 
TAZ maps to NC_000003.12, in the region between 
149235022 to 149454501 and spans 220 kilobases. 
TAZ has 7 exons, ranging in size from 112 bp to 
3754 bp. 
Transcription 
The mRNA transcript spans 5135 bp with 1202 bp 
open reading frame. 
 
TAZ structure domain. TB: TEAD binding domain; WW: WW domain; TA: Transactivation domain, which contains a Gln-rich 
region (194-241 aa) and Coiled-coil region (225-259 aa); PDZB: PDZ-binding domain; S89-LATS phosphorylation site. 
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Protein 
Description 
TAZ is a downstream transcriptional coactivator in 
the Hippo pathway (Kanai et al., 2000; Lei et al., 
2008; Hong and Guan, 2012). TAZ has one WW 
domain which allows its interaction with PPxY 
motif-containing proteins such as LATS kinases in 
the Hippo pathway as well as other transcription 
factors (TFs). Its N-termini contains a Tead-binding 
(TB) domain, through which TAZ can bind to 
TEAD, which is a well-known TF involved in cell 
proliferation and anti-apoptosis. In its C-termini, 
there is a Transcriptional Activation (TA) domain 
which contains a Gln-rich region (amino acid (aa.) 
194-241) and Coiled-coil region (aa. 225-259). 
From 394 to aa. 400 of TAZ, there is a PDZ-
binding domain, which has been found important 
for transcriptional coactivating function of TAZ 
(Wang et al., 2009; Liu et al., 2011). 
Expression 
TAZ is expressed in various tissues, and high 
expression of TAZ has been found in thyroid, 
kidney, heart, placenta and lung. 
Localisation 
TAZ localizes in both cytoplasm and nucleus. 
Normally, in the nucleus, TAZ can possess its 
transcription-activating function and help initiate 
target genes' expressions through binding with 
related transcriptional factors. And the localization 
of TAZ can be regulated by cell-cell contact. Once 
cells get confluent (high cell-cell contact), the 
Hippo pathway will be activated (Zhao et al., 
2011). As a result, TAZ will be phosphorylated on 
S89, initiating its binding with 14-3-3 (Lei et al., 
2008; Zhao et al., 2008), which will anchor TAZ in 
the cytoplasm. Besides, the interaction with some 
proteins, such as AMOT and ZO-1, can also 
localize TAZ to cell membrane (Chan et al., 2011; 
Remue et al., 2010). 
Function 
TAZ functions as an oncogene. Over-expression of 
TAZ induces increased cell proliferation, epithelial-
mesenchymal transition (EMT), cell migration and 
transformation (Chan et al., 2009; Lai et al., 2011). 
In addition, enhanced levels of TAZ causes drug 
resistance by activating CTGF and Cyr61 (Lai et 
al., 2011). 
TAZ is also involved in mesenchymal stem cell 
differentiation. TAZ can activate TF RUNX2 to 
induce osteoblast differentiation, while TAZ binds 
and inhibits PPARG TF, which further blocks 
adipocyte differentiation. Besides, TAZ also 
regulates myoblast differentiation by enhancing TF 
MyoD-dependent myogenic gene expression (Hong 
et al., 2005; Jung et al., 2009; Cho HH et al., 2010). 
TAZ relates to tissue homeostasis and development 
as well. TAZ knockout mice develop Polycystic 
Kidney Disease (PKD) and emphysema, suggesting 
an important role of TAZ in renal and lung 
development (Liu et al., 2011). 
TAZ also plays a role in mechanotransduction. 
Extracellular matrix stiffness or confined 
adhesiveness can cause TAZ retention in nuclear, 
which, therefore contributes to cell proliferation, 
mesenchymal stem cell differentiation as well as 
cancer malignant progression (Dupont et al., 2011). 
Homology 
TAZ gene is conserved across species. Homologous 
proteins have been found in chimpanzee, dog, cow, 
mouse, rate, chicken and zebrafish. 
Mutations 
Note 
TAZ has a missense mutation (F299V), which was 
detected at 7% and 10% in primary mammary 
tumor and xenograft respectively, as well as 28% 
mutant allele frequency in metastatic breast cancers 
(Ding et al., 2010). 
Implicated in 
Non-small cell lung cancer 
Note 
High level of TAZ has been found in different non-
small cell lung cancer (NSCLC) cell lines.  
TAZ overexpression in immortalized non-
tumorigenic lung epithelial cells causes increased 
cell proliferation and transformation, whereas TAZ 
knockdown in NSCLC cells significantly reduces 
tumor cell proliferation and tumor growth in nude 
mice (Zhou et al., 2011).  
Significantly, TAZ expression was found associated 
with lung adenocarcinoma, metastasis, poorer 
differentiation and poor prognosis (Xie et al., 
2012). Lung cancer patients with negative TAZ 
expression have prolonged overall survival (Lau et 
al., 2014). 
Colorectal cancer 
Note 
High levels of TAZ mRNA are significantly 
correlated with shorter survival in colorectal cancer 
patients. This was due to the increased levels of 
TAZ downstream target genes CTGF and AXL, 
which are involved in colorectal cancer 
development (Yuen et al., 2013). 
Breast cancer 
Note 
TAZ has been found correlated with breast cancers. 
The breast cancer cell lines have high expression of 
TAZ and 20% of breast cancer samples have TAZ 
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overexpression (Chan et al., 2009). TAZ causes 
increased cell migration through activation of 
BMP4, and resistance to chemotherapeutic drug 
Taxol through downstream Cyr61 and CTGF (Lai 
et al., 2011; Lai and Yang, 2013). TAZ can also 
cause increased cell proliferation and tumorigenesis 
by activating KLF5 through inhibition of KLF5 
degradation (Zhao et al., 2012). Also, TAZ has 
been suggested to play a role in breast cancer stem 
cell self-renewal and tumor-initiation capabilities 
(Cordenonsi et al., 2011; Bartucci et al., 2014). 
Moreover, TAZ is also found amplified in 44% 
basal-like and 30% luminal breast cancer (Skibinski 
et al., 2014). 
Tongue squamous cell carcinoma 
(TSCC) 
Note 
TSCC cells and specimens have significantly higher 
expression of TAZ than those in non-cancerous 
cells and normal tongue mucosa. Overexpression of 
TAZ in TSCC was significantly associated with 
tumor size, clinical stage and reduced overall and 
disease-free survival (Wei et al., 2013). 
Polycystic kidney disease (PKD) 
Note 
TAZ knockout mice develop PKD during 
development. NEK1 kinase can phosphorylate 
TAZ, which can disable TAZ's role in promoting 
the degradation of PC2, a protein involved in 
ciliogenesis. The proper balance of NEK1 and TAZ 
will help keep a good level of PC2, which will 
protect kidney from PKD (Tian et al., 2007; Yim et 
al., 2011). 
Holt-Oram syndrome 
Note 
TAZ can interact with and activate transcription 
factor TBX5, which is essential in cardiac and limb 
development. In Holt-Oram syndrome, TBX5 has a 
truncated mutation, which will lose its interaction 
with TAZ and therefore, fail to activate genes 
involved in cardiac and limb development 
(Murakami et al., 2005). 
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